Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
monoclonal antibody RAV12 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RAV12 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| monoclonal antibody RAV12 | BIOLOGICAL | Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks |
DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma * Metastatic or recurrent disease * Not curable by standard therapies * Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease * Patients with colorectal or breast adenocarcinoma...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Monoclonal antibody RAV12 is an investigational monoclonal antibody being studied for the treatment of cancer, specifically metastatic or recurrent adenocarcinoma. It is in Phase 1 clinical development and is not yet approved by the FDA.
Monoclonal antibody RAV12 is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MGNX.
Monoclonal antibody RAV12 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed.
Monoclonal antibody RAV12 has been studied in one completed Phase 1 clinical trial, NCT00101972, which evaluated the drug in patients with metastatic or recurrent adenocarcinoma. The trial enrolled 53 participants in the United States.
Yes, monoclonal antibody RAV12 is the same as RAV12. The drug is referred to as monoclonal antibody RAV12 in development documentation, and the clinical trial NCT00101972 lists it as RAV12.